Arcutis Biotherapeutics (ARQT) Non-Current Assets (2019 - 2026)

Arcutis Biotherapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $21.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 7.4% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $85.1 million (up 48.5% YoY), while the FY2025 annual figure was $21.7 million, up 66.36% from the prior year.
• Non-Current Assets for Q1 2026 stood at $21.9 million, up from $21.7 million in the prior quarter.
• The five-year high for Non-Current Assets was $21.9 million in Q1 2026, with the low at $5.0 million in Q2 2022.
• The 5-year median for Non-Current Assets is $11.9 million (2022), against an average of $13.7 million.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 134.64% in 2023, then slipped 13.98% in 2024.
• Arcutis Biotherapeutics' Non-Current Assets stood at $11.9 million in 2022, then slipped by 7.87% to $10.9 million in 2023, then rose by 19.53% to $13.1 million in 2024, then jumped by 66.36% to $21.7 million in 2025, then grew by 0.95% to $21.9 million in 2026.
• Business Quant data shows ARQT's Non-Current Assets at $21.9 million in Q1 2026, $21.7 million in Q4 2025, and $21.8 million in Q3 2025.